CTTC — Calmare Therapeutics Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- $5.59m
- $1.11m
Annual income statement for Calmare Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2012 December 31st | 2013 December 31st | 2014 December 31st | 2015 December 31st | 2016 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.913 | 0.653 | 1.05 | 0.891 | 1.11 |
| Cost of Revenue | |||||
| Gross Profit | 0.546 | 0.38 | 0.604 | 0.612 | 0.788 |
| Selling / General / Administrative Expenses | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 3.92 | 3.32 | 4.46 | 4.57 | 4.93 |
| Operating Profit | -3 | -2.67 | -3.41 | -3.68 | -3.83 |
| Net Income Before Taxes | -3 | -2.67 | -3.41 | -3.68 | -3.83 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -3 | -2.67 | -3.41 | -3.68 | -3.83 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -3 | -2.67 | -3.41 | -3.68 | -3.83 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -3 | -2.67 | -3.41 | -3.68 | -3.83 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.2 | -0.157 | -0.142 | -0.132 | -0.133 |
| Dividends per Share |